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Abstract
A human cDNA for amino acid transport system x3C was isolated from diethyl maleate-treated human glioma U87 cells.
U87 cells expressed two variants of system x3C transporters hxCTa and hxCTb with altered C-terminus regions probably
generated by the alternative splicing at 3P-ends. Both hxCTa and hxCTb messages were also detected in spinal cord, brain
and pancreas, although the level of hxCTb expression appears to be lower than that of hxCTa in these tissues. When
expressed in Xenopus oocytes, hxCTb required the heavy chain of 4F2 cell surface antigen (4F2hc) and exhibited the Na-
independent transport of L-cystine and L-glutamate, consistent with the properties of system x3C . In agreement with this,
137 kDa band was detected by either anti-xCT or anti-4F2hc antibodies in the non-reducing condition in western blots,
whereas it shifted to 50 kDa or 90 kDa bands in the reducing condition, indicating the association of two proteins via
disulfide bands. We found that the expression of xCT was rapidly induced in U87 cells upon oxidative stress by diethyl
maleate treatment, which was accompanied by the increase in the L-cystine uptake by U87 cells. Because of this highly
regulated nature, xCT in glial cells would fulfill the task to protect neurons against oxidative stress by providing suitable
amount of cystine to produce glutathione. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
It has been proposed that the transport of cystine
through the plasma membrane is crucial to maintain
intracellular glutathione (GSH) levels [1]. GSH is a
tripeptide radical scavenger synthesized intracellu-
larly from glutamate, cysteine and glycine. Because
cysteine is easily oxidized to form cystine in the
extracellular environment, cystine transport mecha-
nisms are essential to provide cells with cysteine for
GSH synthesis [1]. The amino acid transport system
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x3C has been proposed to be responsible for the cys-
tine transport through the plasma membrane. System
x3C mediates an amino acid exchange and prefers
cystine and glutamate as its substrates [1].
Recently, a cDNA which encodes a transporter
subserving the system x3C has been isolated from
mouse peritoneal macrophages treated with diethyl
maleate and lipopolysaccharide [2]. The transporter
designated as xCT requires the heavy chain of 4F2
cell surface antigen (4F2hc) for its functional expres-
sion in Xenopus oocytes [2] and belongs to the family
of amino acid transporters which associates with the
type II membrane glycoproteins such as 4F2hc and
rBAT (related to b0; amino acid transporters) [3^8].
It has been shown that xCT is upregulated on the
GSH depletion by diethyl maleate treatment in the
mouse peritoneal macrophages [2,9,10]. In brain, it
has been proposed that system x3C is upregulated in
glial cells upon the oxidative stress and plays an es-
sential roles to protect neurons against oxidative
stress [11^13]. In this study, we have isolated a
cDNA for xCT from diethyl maleate-treated human
glioma U87 cells and demonstrated that the expres-
sion of xCT is induced by oxidative stress in the
glioma cell line.
2. Materials and methods
2.1. cDNA cloning
By means of guanidinium isothiocyanate method
using cesium-tri£uoroacetic acid (Pharmacia), total
RNA was prepared from human glioma U87 cells
treated with 0.1 mM diethyl maleate for 8 h in Dul-
becco’s modi¢ed Eagle’s medium containing 10% fe-
tal bovine serum [14]. The oligo dT-primed cDNA
library was prepared from U87 cell poly(A) RNA
selected by oligo(dT) cellulose chromatography
(Pharmacia) using Superscript Choice System (Gibco
BRL) [4,15]. The synthesized cDNA was ligated to
VZipLox EcoRI arms (Gibco BRL). Screening
cDNA library and isolation of positive plaques
were performed as described elsewhere [14]. A
cDNA fragment corresponding to 897^1107 bp of
mouse xCT (GenBank/EMBL/DDBJ Data Bank ac-
cession number AB022345) [2] was ampli¢ed by re-
verse transcription^polymerase chain reaction (RT^
PCR) on the mouse brain poly(A) RNA using syn-
thetic oligonucleotide primers 5P-TCCTAACCTT-
TTGCAAGCTCACA-3P and 5P-TCAGGGTTGTC-
TACTTCTTCAG-3P (corresponding to nucleotides
897^919 and 1086^1107 of mouse xCT cDNA, re-
spectively). The PCR product was used as a probe
for screening the cDNA library. cDNAs in positive
VZipLox phages were rescued into plasmid pZL1.
The cDNA was sequenced in both direction by
dye terminator cycle sequencing method (Perkin
Elmer and Applied Biosystems). Transmembrane
regions were predicted on the human xCT amino
acid sequence based on TopPred algorithm
[16,17].
2.2. Northern analysis
For Northern blot analysis, the HpaI/NcoI frag-
ment corresponding to 196^954 bp of hxCTb
cDNA was labeled with [32P]dCTP using T7Quick
prime kit (Pharmacia). Human Multiple Tissue
Northern Blots (Clontech) were hybridized with the
probe and processed following the manufacturer’s
instructions.
2.3. Detection of spliced variants by RT^PCR
To examine the expression of spliced variants,
PCR primers were designed which are unique to
each spliced fragment, 5P-TCCCTATTTTGTGT-
CTCCCC-3P (antisense primer A) and 5P-GCCCA-
TAAACACCATCTGGC-3P (antisense primer B)
designed on C-terminus regions of hxCTa (corre-
sponding to nucleotides 1776^1795 of GenBank/
EMBL/DDBJ Data Bank accession number
AB026891) and hxCTb (corresponding to nucleo-
tides 1689^1708 of GenBank/EMBL/DDBJ no.
AB040875), respectively. The sense primer (primer
C) which is common to hxCTa and hxCTb was de-
signed: 5P-CACCTTCCAGAAATCCTCTC-3P cor-
responding to the nucleotide sequences of 1283^
1302 of hxCTa and 1183^1202 of hxCTb. The ¢rst-
strand cDNA was synthesized from human brain,
human spinal cord and human pancreas poly(A)
RNA (Clontech) and poly(A) RNA of diethyl mal-
eate-treated U87 cells (see above) using oligo dT12ÿ18
as a primer. PCR ampli¢cation of the cDNA was
performed as described elsewhere [15] using the prim-
BBAMEM 78107 28-5-01
J.Y. Kim et al. / Biochimica et Biophysica Acta 1512 (2001) 335^344336
er sets: sense primer C and antisense primer A, or
sense primer C and antisense primer B.
2.4. Anti-peptide antibody
Oligopeptides [MVRKPVVATISKGGYC] corre-
sponding to amino acid residues 1^15 of mouse
xCT [2] and [EPHEGLLLRFPYAAC] correspond-
ing to amino acid residues 516^529 of human
4F2hc (GenBank/EMBL/DDBJ accession no.
AB018010) were synthesized. Only a single amino
acid is altered in human xCT in the region (Ser8
for human xCT vs. Ala8 for mouse xCT). The
C-terminus cysteine residues were introduced for
conjugation with keyhole limpet hemocyanin. The
anti-peptide antibodies were generated as described
elsewhere [5,8,18]. Antisera were a⁄nity-puri¢ed as
described [8,19].
2.5. Western blot analysis
For Western blot analysis, U87 cell membranes
were prepared as described elsewhere [8,20], with mi-
nor modi¢cations. Brie£y, U87 cells treated with
0.1 mM diethyl maleate for 16 h as described above
were homogenized in 9 volumes of 50 mM Tris^HCl
(pH 7.5), 25 mM KCl, 1 mM MgCl2, 1 mM phenyl-
methylsulfonyl £uoride and 0.25 M sucrose, with 15
strokes of a Dounce homogenizer. The homogenate
was centrifuged for 10 min at 8000Ug, and the
supernatant was centrifuged further for 1 h at
100 000Ug. After centrifugation, the membrane pel-
let was resuspended in 0.25 M sucrose, 100 mM KCl,
5 mM MgCl2 and 50 mM Tris (pH 7.4). The protein
samples were heated at 100‡C for 5 min in sample
bu¡er either in the presence or absence of 5% 2-mer-
captoethanol and subjected to sodium dodecyl sul-
fate (SDS)^polyacrylamide gel electrophoresis. The
separated proteins were transferred electrophoreti-
cally to a Hybond-P PVDF transfer membrane
(Amersham). The membrane was then treated with
non-fat dried milk and diluted a⁄nity-puri¢ed anti-
xCT antibody (1:1000) or anti-h4F2hc antiserum
(1:20 000). The membrane was then treated with
horseradish peroxidase-conjugated anti-rabbit IgG
as a secondary antibody (Jackson Immuno Research
Laboratories). The signals were detected with an
ECL Plus system (Amersham) [5,8]. To verify the
speci¢city of immunoreactions by absorption experi-
ments, the membranes were treated with primary
antibodies in the presence of antigen peptides
(50 Wg/ml) [5,8].
2.6. Functional characterization
Functional characteristics of hxCTb were exam-
ined by Xenopus oocyte expression. cRNAs for
hxCTb and human 4F2hc were obtained by in vitro
transcription using SP6 RNA polymerase for hxCTb
in plasmid pZL1 linearized with RsrII and T7 RNA
polymerase for human 4F2hc in pZL1 linearlized
with HindIII as described elsewhere [14]. Xenopus
oocyte expression studies and uptake measurements
were performed as described [14,21]. hxCTb cRNA
(12.5 ng) and human 4F2hc cRNA (12.5 ng) were
solely injected or co-injected to each oocyte. The
uptake of L-[14C]cystine or L-[14C]glutamate (New
England Nuclear) was measured 3 days after injec-
tion of the cRNAs. Groups of 6^8 oocytes were in-
cubated in 500 Wl of standard uptake solution (NaCl
100 mM, KCl 2 mM, CaCl2 1 mM, MgCl2 1 mM,
HEPES 10 mM, Tris 5 mM, pH 7.4) or Na-free
uptake solution in which NaCl in the standard up-
take solution was replaced by choline-Cl, containing
0.25 WCi of radiolabeled compounds. The uptakes
were measured for 30 min and the values were ex-
pressed as pmol/oocyte per minute. Each data point
in the ¢gures represents the mean þ S.E.M. of uptake
values (n = 6^8).
2.7. Evaluation of the e¡ect of diethyl maleate
treatment
In order to examine the e¡ect of diethyl maleate
treatment, total RNA was prepared using a RNA
preparation kit Isogen (Nippon-Gene, Japan) from
U87 cells incubated with 0.1 mM diethyl maleate in
Dulbecco’s modi¢ed Eagle’s medium containing 10%
fetal bovine serum for 4, 8, 16 and 24 h [2,10]. The
total RNA (10 Wg/lane) was separated on a 1% aga-
rose gel in the presence of 2.2 M formaldehyde and
was blotted onto a nitrocellulose ¢lter (Schleicher
and Schuell) [14]. The ¢lter was hybridized with
32P-labeled hxCTb cDNA fragment described above
for 20 h at 42‡C. The hybridization solution con-
tained 5USSC, 3UDenhardt’s solution, 0.2% SDS,
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10% dextransulfate, 50% formamide, 0.01% Anti-
foam B (sigma), 0.2 mg/ml denatured salmon sperm
DNA (Wako, Japan), 2.5 mM sodium pyrophos-
phate and 25 mM MES, pH 6.5. The ¢lters were
washed in 0.1USSC/0.1% SDS at 65‡C [14]. After
stripping, the ¢lter was rehybridized with human
L-actin probe (Clontech). Based on the densitometric
analysis of the hybridization using Bio-Imaging
Analyzer System BAS2000 (FujiX), the levels of
hxCT mRNA expression were normalized by those
of the L-actin mRNA expression.
The e¡ect of diethyl maleate treatment was further
evaluated on the L-[14C]cystine uptake by U87 cells.
U87 cells were seeded on 24-well plates (1U105/well)
in Dulbecco’s modi¢ed Eagle’s medium containing
10% fetal bovine serum. After 2 days of culture,
the cells were incubated with 0.1 mM diethyl maleate
in Dulbecco’s modi¢ed Eagle’s medium containing
10% fetal bovine serum for 4, 8, 16 and 24 h. For
the measurement of L-[14C]cystine uptake, the cells
were washed twice with regular uptake solution (Dul-
becco’s modi¢ed phosphate-bu¡ered saline (Dulbec-
co’s PBS) supplemented with 5 mM glucose) after the
removal of growth medium, and preincubated for
10 min at 37‡C. Then, the medium was replaced by
the regular uptake solution containing L-[14C]cystine
(100 WM). The uptake was measured for 2 min and
expressed as pmol/mg protein per minute. The up-
take reaction was terminated by removing uptake
medium followed by washing three times with ice-
cold regular uptake solution. Then, cells were solu-
bilized with 0.1 N NaOH and radioactivity was
counted [8].
3. Results
3.1. Structural properties of hxCT
A cDNA clone with 2000 bp insert isolated from
diethyl maleate-treated human glioma U87 cells con-
tained an open reading frame from nucleotide 136 to
1617 encoding a putative 495-amino-acid protein
designated as hxCTb (human xC-type transporter b)
which exhibited 86% amino acid sequence identity to
mouse xCT [2] (Fig. 1). As shown in Fig. 1, 12 trans-
membrane regions were predicted on hxCTb amino
acid sequence. There is a conserved cysteine residue
(hxCTb amino acid residue 158) in the putative
extracellular loop between predicted transmembrane
domains 3 and 4, which is supposed to link to 4F2hc
via a disul¢de bond [22]. A cAMP-dependent phos-
phorylation site (Thr45) and a protein kinase C-de-
pendent phosphorylation site (Thr103) are predicted
in the intracellular domains (Fig. 1).
We found that the C-terminus sequence of hxCTb
is di¡erent from that of the already published human
xCT [23,24] (Fig. 2A), suggesting the alternative
splicing at the 3P-ends. Because of this alteration,
C-terminus 22 amino acid residues of the human
Fig. 1. Structural features of a human xCT. The deduced se-
quence of hxCTb is shown aligned with that of mouse xCT [2].
Membrane spanning domains predicted for hxCTb are indicated
by lines numbered 1^12. Potential cAMP-dependent phosphory-
lation sites are predicted at residues 45 and 346, in which Thr
45 is predicted to be located intracellularly (labeled with #). Po-
tential protein kinase C-dependent phosphorylation sites are
predicted at residues 65, 103, 187, 226 and 308, among which
Thr 103 is located in the predicted intracellular domain (labeled
with *).
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xCT protein reported by Sato et al. and Bridges et al.
[23,24] (referred to as hxCTa in this paper) were
replaced by 13 amino acid residues in hxCTb (Fig.
2A,B). Three polyadenylation sites (AATAAA) were
identi¢ed in the 3P-untranslated region of hxCTb,
whereas they were not found in hxCTa (GenBank/
EMBL/DDBJ Data Bank accession number
AB026891) (Fig. 2B).
3.2. Tissue distribution of expression
The distribution of expression of xCT in human
tissues was analyzed by Northern blot. The cDNA
fragment corresponding to the region of mRNA
common to both hxCTb and hxCTa was used as a
probe. The probe hybridized to the long message at
8.5 kb in brain, spinal cord and pancreas (Fig. 3A).
In order to examine the expression of spliced var-
iants, RT^PCR was performed using primers speci¢c
to each spliced variant (Fig. 2B). As shown in Fig.
3B, PCR products corresponding to both hxCTa and
hxCTb were detected in diethyl maleate-treated U87
cells, human brain, human spinal cord and human
pancreas, indicating that both spliced variants were
expressed in these cells and tissues. The level of ex-
pression of hxCTb, however, appeared to be lower
than that of hxCTa particularly in brain, spinal cord
and pancreas (Fig. 3B).
3.3. The association of hxCT and 4F2hc
The antibody raised against N-terminus region of
xCT recognized a prominent band at 137 kDa and a
faint band at 50 kDa in the non-reducing condition,
whereas the 137-kDa band disappeared and shifted
to 50 kDa in the reducing condition (Fig. 4). Anti-
4F2hc antibody also recognized 137 kDa band in the
non-reducing condition. In the reducing condition,
90-kDa band was detected by the anti-4F2hc anti-
body (Fig. 4). All these bands were not detected in
Fig. 3. Tissue distribution of expression. (A) High-stringency
Northern blot analysis of xCT expression in humans. The
8.5 kb band was detected in brain, spinal cord and pancreas.
The cDNA fragment corresponding to the region of mRNA
common to both hxCTb and hxCTa was used as a probe. (B)
RT^PCR of poly(A) RNAs from U87 cells, human brain, hu-
man spinal cord and human pancreas using primers speci¢c to
hxCTb (primers B and C) and hxCTa (primers A and C). The
¢gure shows the ethidium bromide-stained agarose gel electro-
phoresis of the PCR products using the primers B and C (la-
beled as ‘b’), and the primers A and C (labeled as ‘a’).
Fig. 2. Spliced variants of human xCT. (A) Comparison of nu-
cleotide sequences corresponding to C-termini of hxCTb and
hxCTa [23,24]. Deduced amino acid sequences are attached to
the nucleotide sequences. The broken lines indicate the pre-
dicted points of alternative splicing. *, Stop codon. (B) Struc-
tures of human xCT mRNAs corresponding to hxCTb and
hxCTa. Polyadenylation sites (AATAAA) are identi¢ed at 1621,
1798 and 1956 of the hxCTb nucleotide sequence and indicated
by arrowheads. PCR primers labeled with A, B and C are indi-
cated at the positions on which they are designed. ATG, start
codon; Stop, stop codon; left, 5P-end; right, 3P-end.
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the absorption experiments in which the membranes
were treated with anti-xCT or anti-4F2hc antibodies
in the presence of antigen peptides, con¢rming
the speci¢city of the immunoreactions (data not
shown).
3.4. Functional properties
In order to determine the functional properties of
hxCTb, hxCTb was expressed in Xenopus oocytes. As
shown in Fig. 5A, hxCTb required 4F2hc for its
functional expression. Although hxCTb by itself
did not exhibit amino acid transports, the co-
expression of hxCTb and 4F2hc resulted in the in-
duction of transport activity for L-[14C]glutamate
and L-[14C]cystine. Thus, the functional properties
of hxCTb were examined by coexpressing hxCTb
with 4F2hc.
The uptake of L-[14C]glutamate mediated by
hxCTb was not dependent on Na (Fig. 5B). The
substrate selectivity of hxCTb was investigated by
inhibition experiments in which 50 WM L-[14C]-
glutamate uptake was measured in the presence of
5 mM non-labeled amino acids. As shown in Fig.
5C, hxCTb-mediated glutamate uptake was inhibited
at high levels by L-glutamate and L-cystine and at a
lower level by L-aspartate, whereas D-glutamate,
D-aspartate, L-alanine, L-leucine and L-lysine did
not inhibit hxCTb-mediated glutamate uptake.
3.5. Induction of hxCT expression by oxidative stress
In order to examine the e¡ect of diethyl maleate
treatment on the expression of xCT mRNA in U87
cells, Northern blot analysis was performed on the
Fig. 5. Functional properties of hxCTb. (A) Functional ex-
pression of hxCTb in Xenopus oocytes. The uptake of
L-[14C]glutamate (shaded column) and L-[14C]cystine (solid col-
umn) was measured at the concentration of 100 WM in Na-
free uptake solution on the Xenopus oocytes injected with water
(labeled as ‘water’), hxCTb cRNA (‘hxCTb’), 4F2hc cRNA
(‘4F2hc’) or both hxCTb cRNA and 4F2hc cRNA
(‘hxCTb+4F2hc’) 3 days after injection. The co-expression of
hxCTb and 4F2hc resulted in the induction of activity for the
uptake of L-glutamate and L-cystine. (B) Na-dependence of
hxCTb-mediated L-[14C]glutamate transport. The hxCTb-medi-
ated uptake of 100 WM L-[14C]glutamate measured in the regu-
lar-uptake solution (labeled as ‘Na’) was not altered in the up-
take medium in which Na was replaced by choline (‘choline’).
(C) Inhibition of hxCTb-mediated uptake of L-[14C]glutamate
by non-labeled amino acids. The LAT1-mediated L-[14C]gluta-
mate uptake (50 WM) was measured in the presence of 5 mM
non-radiolabeled L-amino acids and expressed as percent of the
control L-leucine uptake in the absence of inhibitors (‘(3)’).
The L-glutamate uptake was inhibited by L-glutamate, L-cystine
and L-aspartate. L-CssC, L-cystine.
Fig. 4. Western blot analyses under reducing and non-reducing
conditions. Western blot analyses were performed using an
anti-xCT antibody (labeled as ‘hxCT’) and an anti-4F2hc anti-
body (labeled as ‘4F2hc’) on the membrane fractions prepared
from human glioma U87 cells in the presence (labeled as ‘+’)
or absence (labeled as ‘3’) of 2-mercaptoethanol.
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total RNA prepared from U87 cells treated with 0.1
mM diethyl maleate for 4, 8, 16 and 24 h. As shown
in Fig. 6A,B, the levels of xCT mRNA increased
during diethyl maleate treatment with the peak value
at 16 h.
The e¡ect of diethyl maleate treatment was also
examined on the L-[14C]cystine uptake by U87 cells.
As shown in Fig. 6C, L-[14C]cystine uptake was in-
creased at 16 and 24 h.
4. Discussion
The human system x3C transporter hxCTb identi-
¢ed in the present study in glioma U87 cells exhibits
an altered C-terminus sequence compared with that
of mouse xCT isolated from macrophages [2] because
of the proposed alternative splicing at the 3P-ends. In
contrast, the other spliced variant hxCTa identi¢ed
in human ¢broblasts and human retinal pigment ep-
ithelial cell line ARPE-19 possesses the identical C-
terminus to that of the mouse xCT [23,24]. In human
tissues, xCT is expressed in spinal cord, brain and
pancreas, consistent with the result from mouse
Northern blot in which xCT message was detected
only in brain [2] (Fig. 3A). In brain, spinal cord and
pancreas, both spliced variants were demonstrated to
be expressed as well as in U87 glioma cells, although
the level of expression of hxCTb seems lower than
that of hxCTa in brain, spinal cord and pancreas
Fig. 6. Diethyl maleate-induced increase in the level of human
xCT mRNA. (A) Northern blot analyses were performed using
a 32P-labeled human xCT probe on the total RNA separated
from human glioma U87 cells treated with 0.1 mM diethyl mal-
eate for 4, 8, 16 and 24 h. ‘0 hr’ indicates U87 cells without di-
ethyl maleate treatment. The same blots were rehybridized with
human L-actin probe (bottom). (B) The levels of human xCT
mRNA at 8.5 kb are shown by normalizing with the levels of
L-actin mRNA for each sample. The ordinate indicates the val-
ue of the normalized human xCT mRNA level at each time
point compared, in the same series of experiments, with that at
0 h (100%). The values are expressed as mean þ S.E.M. of three
separate experiments. (C) The e¡ect of diethyl maleate treat-
ment on L-[14C]cystine uptake by U87 cells. U87 cells were
treated with diethyl maleate in the same condition as that for
A and B. Each value represents mean þ S.E.M. (n = 4). Asterisks
indicate statistical signi¢cance between the uptake at 4, 8, 16 or
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(Fig. 3B). Because typical polyadenylation sites are
not identi¢ed in the 3P-untranslated region of hxCTa
while the 3P-untranslated region of hxCTb contains
polyadenylation sites, it is reasonable to assume that
hxCTa and hxCTb correspond to the long message
(8.5 kb) and the short message (2.8 kb) detected in
U87 cells, respectively (Fig. 6A). This is consistent
with the observation that the long message was pre-
dominant in brain, spinal cord and pancreas in which
the expression of hxCTa seems much higher than
that of hxCTb (Fig. 3A,B).
It is notable that the C-terminus of hxCTa con-
tains many charged residues whereas that of hxCTb
is rather hydrophobic, as is observed for the spliced
variants of mouse glutamate transporter GLT-1 [15].
In mouse GLT-1, the coexpression of two spliced
variants with altered C-termini resulted in the in-
crease in the Vmax value of the transport. It would
be interesting to know whether the two hxCT var-
iants are expressed in the same cells and the ratio of
expression of each variant a¡ects the transport activ-
ity.
Because the members of LAT family except BAT1/
b0;AT are associated with the 4F2hc, they are pro-
posed to be the light chains of 4F2 heterodimeric cell
surface antigen [3^8,25^27]. Among the members of
LAT family, system yL transporter yLAT1, sys-
tem asc transporter Asc-1 and system L transporter
LAT1 have been demonstrated to be linked to 4F2hc
via a disul¢de bond [5,25,26]. In the present study,
using speci¢c antibodies raised against xCT and
4F2hc, we showed that the bands at 137 kDa de-
tected in the non-reducing condition corresponding
to the heterodimeric complex of xCT and 4F2hc shift
to 50 kDa and 90 kDa corresponding to the mono-
mers of xCT and 4F2hc, respectively, in the reducing
condition, which indicates the association of xCT
and 4F2hc via a disul¢de bond (Fig. 4). This is con-
sistent with the results from the functional expression
indicating that xCT requires 4F2hc for its functional
expression (Fig. 5A and reference [2,23,24]). In the
presence of 4F2hc, hxCTb exhibits the Na-inde-
pendent transport of L-glutamate and L-cystine with
the properties of system x3C (Fig. 5), consistent with
hxCTa and mouse xCT [2,23,24].
The expression of xCT has been shown to be in-
ducible in mouse macrophages, human ¢broblasts
and ARPE-19 human retinal pigment epithelial cells
[2,23,24]. In the present study, U87 glioma cells are
examined as an additional human cell model on
which the responses to lipopolysaccharide and oxida-
tive stress have been well studied [28^30]. The expres-
sion of xCT in U87 glioma cells is highly inducible
and upregulated with the peak value at 16 h upon the
oxidative stress caused by diethyl maleate treatment
(Fig. 6A,B). This is consistent with the observations
for mouse peritoneal macrophages, human ¢bro-
blasts and ARPE-19 human retinal pigment epitheli-
al cells in which xCT is upregulated on the oxidative
stress or the cell activation by lipopolysaccharide
[2,23,24]. In the present study, we further demon-
strated that the diethyl maleate treatment also ele-
vated the L-[14C]cystine uptake by U87 cells (Fig.
6C). This e¡ect is, however, with slower onset and
lasting longer compared with the e¡ect on the
mRNA level (Fig. 6C), which is reasonable when
considering that functional xCT proteins are in-
creased following the mRNA rise and stay longer
than the messages.
In the central nervous system, it has been pro-
posed that glial cells play critical roles to maintain
neuronal GSH levels by providing neurons with cys-
teine because neurons have less activity in system x3C
[31,32]. Glial cells ful¢ll this task by producing GSH
and releasing it to the extracellular space in the vi-
cinity of neurons [32,33]. Although system x3C is es-
sential to provide cells with cystine for GSH synthe-
sis, the over-function of system x3C would be
damaging neurons by increasing extracellular gluta-
mate concentration because this exchanger releases
glutamate through the cystine/glutamate exchange
mechanism [34]. Therefore, the system x3C activity
in glial cells needs to be regulated to meet just the
requirement. In the present study, we demonstrated
that the xCT mRNA level is transiently increased in
U87 glioma cells by the oxidative stress. It would be
an important issue to examine whether xCT is regu-
lated in the same manner in glial cells in vivo to
protect neurones against oxidative stress.
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